Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
LongeVC is a Washington D.C.-based venture capital firm that specializes in investing in early-stage companies within the biotechnology and longevity sectors. Founded with the mission to support innovative founders, LongeVC aims to facilitate the market introduction of groundbreaking biotech solutions. The firm has established a strong reputation for its commitment to advancing personalized medicine and advanced diagnostics. With a portfolio comprising 25 companies, LongeVC is actively engaged in the biotechnology landscape, focusing on pre-seed, seed, seed-plus, and Series A funding stages. The firm’s leadership is dedicated to identifying and nurturing startups that are pioneering advancements in the molecular and cellular mechanisms of aging. By leveraging its extensive network and industry expertise, LongeVC provides valuable resources and support to its portfolio companies, helping them navigate the complexities of the biotech market.
LongeVC's investment focus is centered on early-stage companies that are developing innovative solutions in the fields of personalized medicine, advanced diagnostics, and foundational platform technologies. The firm is particularly interested in pre-clinical and clinical stage drug development companies that explore the molecular and cellular mechanisms of aging. This includes investments in startups that are working on integrated healthcare solutions aimed at accelerating drug discovery and testing processes. LongeVC seeks to partner with visionary founders who are committed to transforming the healthcare landscape through cutting-edge technology and research. The firm’s investment strategy emphasizes the importance of scientific rigor and market viability, ensuring that the companies they back are not only innovative but also positioned for success in a competitive market.
LongeVC boasts a diverse portfolio of 25 companies that are at the forefront of innovation in biotechnology and longevity. Notable investments include Trogenix, which specializes in precision cancer treatments, and Stealth Company, known for its work on in vivo biofactories. Another significant portfolio company is CatenaBio, which is focused on creating novel therapeutics. Other key players in LongeVC's portfolio include Constructive Bio, Turn.bio, ProtonIntel, and Rubedo Life Sciences, each contributing unique advancements to the biotech field. The firm’s strategic investments reflect its commitment to supporting companies that are not only pioneering new technologies but also addressing critical challenges in healthcare and longevity.
To pitch LongeVC, visit their website at longevc.com or email them at hq@longevc.com. They are open to pitches that align with their focus on biotechnology and longevity, and they encourage founders to present innovative ideas that address significant healthcare challenges.
LongeVC invests in early-stage companies, specifically at the pre-seed, seed, seed-plus, and Series A stages. This allows them to support startups from their inception through critical growth phases.
Founders can pitch LongeVC by visiting their website at longevc.com or by emailing them directly at hq@longevc.com. They welcome pitches that align with their investment focus in biotechnology and longevity.
LongeVC primarily focuses on the biotechnology and longevity sectors. They are particularly interested in companies developing personalized medicine solutions and advanced diagnostics.
While specific check sizes are not disclosed, LongeVC invests in early-stage companies, which typically involves funding amounts that align with pre-seed to Series A stages.
LongeVC's geographic focus is primarily within the United States, targeting innovative biotech companies that are making strides in longevity and healthcare.
LongeVC provides its portfolio companies with access to a network of industry experts, resources, and strategic guidance to help them navigate the complexities of the biotech market and accelerate their growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.